U-VUE Biomarker Datasheet - Arginase-1

Target:Arginase-1
Alternative Name:Liver-type arginase, ARG1
Clone:EPR6672(B)
Isotype:Rabbit IgG
Reactivity:Human
Main cell types:Liver cells, myeloid cells
Subcellular Location:Cytoplasm
Positive control:Tonsil, Liver

Arginase-1 is one of three enzymes that metabolise arginine: ARG1, ARG2, and inducible nitric oxide synthase (iNOS). Arginase-1 induces the breakdown of L-arginine. T cell receptors rely on L-arginine for signaling and cell proliferation. In the context of pro-tumor myeloid cells, Arginase-1 may suppress immune cell signaling and potentially suppress cytotoxic T cell activity.

IHC: Anti-Arginase-1 antibody [EPR6672(B)] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.

IHC: Anti-Arginase-1 antibody conjugate [EPR6672(B)] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.

ISP: Anti-Arginase-1 antibody conjugate [EPR6672(B)] staining normal tonsil FFPE tissue (green). Nuclear counterstain in blue.

References

  1. Steggerda, Susanne M et al. “Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.” Journal for immunotherapy of cancer vol. 5,1 101. 19 Dec. 2017.  DOI: 10.1186/s40425-017-0308-4
  2. Zhao, Chaohui Lisa, et al. “Alanine-Glyoxylate Aminotransferase 1 (AGXT1) Is a Novel Marker for Hepatocellular Carcinomas.” Human Pathology, W.B. Saunders, 5 June 2018. DOI: 10.1016/j.humpath.2018.05.025
  3. Rodríguez, P.C., Ochoa A.C. “Arginine regulation by myeloid derived suppressor cells and tolerance in cancer:  mechanisms and therapeutic perspectives.” Immunological Reviews. 2008; 222:180-91. DOI: 10.1111/j.1600-065X.2008.00608.x

Verification

Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.

This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.

Contact Us